keyword
MENU ▼
Read by QxMD icon Read
search

Daclatasvir

keyword
https://www.readbyqxmd.com/read/29020359/sofosbuvir-based-interferon-free-direct-acting-antiviral-regimens-for-heart-transplant-recipients-with-chronic-hepatitis-c-virus-infection
#1
Chen-Hua Liu, Yih-Sharng Chen, Sheoi-Shen Wang, Chun-Jen Liu, Tung-Hung Su, Hung-Chih Yang, Chun-Ming Hong, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao
We assessed the effectiveness and safety of sofosbuvir (SOF) combined with ledipasvir (LDV) or daclatasvir (DCV) in 12 heart transplant recipients with chronic hepatitis C virus (HCV). The sustained virologic response (SVR12) rate was 100% [95% CI: 75.8%-100%]. All patients tolerated treatment well without interruption, death or serious adverse events.
September 4, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28992878/peginterferon-alfa-2a-for-the-treatment-of-chronic-hepatitis-c-in-the-era-of-direct-acting-antivirals
#2
REVIEW
Yan Huang, Ming-Hui Li, Min Hou, Yao Xie
BACKGROUND: The availability of novel direct-acting antivirals (DAAs) represents a new era of curative hepatitis C virus (HCV) treatment, with over 95% of patients infected with HCV genotype 1 achieving sustained virological response (SVR). Nevertheless, the majority of patients globally are unable to access these treatments because of cost and infrastructure constraints and, thus, remain untreated and uncured. DATA SOURCE: Relevant articles of peginterferon (PegIFN)-based treatments in HCV and sofosbuvir-based treatments, simeprevir, daclatasvir/asunaprevir, ritonavir-boosted paritaprevir/ombitasvir/dasabuvir, and grazoprevir/elbasvir, were searched in PubMed database, including general population and special population...
October 15, 2017: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/28977040/incidence-of-daa-failure-and-the-clinical-impact-of-retreatment-in-real-life-patients-treated-in-the-advanced-stage-of-liver-disease-interim-evaluations-from-the-piter-network
#3
Loreta A Kondili, Giovanni Battista Gaeta, Maurizia Rossana Brunetto, Alfredo Di Leo, Andrea Iannone, Teresa Antonia Santantonio, Adele Giammario, Giovanni Raimondo, Roberto Filomia, Carmine Coppola, Daniela Caterina Amoruso, Pierluigi Blanc, Barbara Del Pin, Liliana Chemello, Luisa Cavalletto, Filomena Morisco, Laura Donnarumma, Maria Grazia Rumi, Antonio Gasbarrini, Massimo Siciliano, Marco Massari, Romina Corsini, Barbara Coco, Salvatore Madonia, Marco Cannizzaro, Anna Linda Zignego, Monica Monti, Francesco Paolo Russo, Alberto Zanetto, Marcello Persico, Mario Masarone, Erica Villa, Veronica Bernabucci, Gloria Taliani, Elisa Biliotti, Luchino Chessa, Maria Cristina Pasetto, Pietro Andreone, Marzia Margotti, Giuseppina Brancaccio, Donatella Ieluzzi, Guglielmo Borgia, Emanuela Zappulo, Vincenza Calvaruso, Salvatore Petta, Loredana Falzano, Maria Giovanna Quaranta, Liliana Elena Weimer, Stefano Rosato, Stefano Vella, Edoardo Giovanni Giannini
BACKGROUND: Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure. AIM: To evaluate DAA failure incidence and the retreatment clinical impact in patients treated in the advanced liver disease stage. METHODS: Data on HCV genotype, liver disease severity, and first and second line DAA regimens were prospectively collected in consecutive patients who reached the 12-week post-treatment and retreatment evaluations from January 2015 to December 2016 in 23 of the PITER network centers...
2017: PloS One
https://www.readbyqxmd.com/read/28953002/sofosbuvir-and-daclatasvir-plus-ribavirin-treatment-improve-liver-function-parameters-and-clinical-outcomes-in-egyptian-chronic-hepatitis-c-patients
#4
Mohamed S Mohamed, Amr S Hanafy, Mohamed A A Bassiony, Samia Hussein
BACKGROUND AND AIMS: Interferon-free direct-acting antivirals (DAA) combination therapies, including sofosbuvir (SOF) and daclatasvir (DCV) therapy, eradicate chronic hepatitis C virus (HCV) in a high percentage of patients, but its impact on improvements in liver function is unclear. The aim of this study was to investigate the changes in clinical and biochemical parameters reflecting liver function and general status in those who achieved HCV eradication by DAA. PATIENTS AND METHODS: From March 2016 to October 2016, 374 chronic hepatitis C patients were enrolled for this prospective, observational study and received SOF, DCV with ribavirin, to evaluate the changes in liver function parameters, international normalized ratio, complete blood count, model for end-stage liver disease, and Child-Turcotte-Pugh scores after achieving a sustained virological response 12 weeks after treatment...
September 25, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28951778/real-world-efficacy-of-daclatasvir-and-asunaprevir-with-respect-to-resistance-associated-substitutions
#5
Hideki Fujii, Atsushi Umemura, Taichiro Nishikawa, Kanji Yamaguchi, Michihisa Moriguchi, Hideki Nakamura, Kohichiroh Yasui, Masahito Minami, Saiyu Tanaka, Hiroki Ishikawa, Hiroyuki Kimura, Shiro Takami, Yasuyuki Nagao, Toshihide Shima, Yoshito Itoh
AIM: To investigate daclatasvir (DCV) and asunaprevir (ASV) efficacy in hepatitis C (HCV) patients, with respect to resistance-associated substitutions (RASs). METHODS: A total of 392 HCV-infected patients from multiple centers were included in this study. We evaluated their clinical courses and sustained virologic responses (SVR) according to pretreatment factors (gender, age, history of interferon-based regimens, platelet counts, level of viremia, pretreatment NA5A:L31, and Y93 substitutions)...
September 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28941023/long-term-follow-up-of-clinical-trial-patients-treated-for-chronic-hcv-infection-with-daclatasvir-based-regimens
#6
K Rajender Reddy, Stanislas Pol, Paul J Thuluvath, Hiromitsu Kumada, Joji Toyota, Kazuaki Chayama, James Levin, Eric J Lawitz, Adrian Gadano, Wayne Ghesquiere, Guido Gerken, Maurizia R Brunetto, Cheng-Yuan Peng, Marcelo Silva, Simone I Strasser, Jeong Heo, Fiona McPhee, Zhaohui Liu, Rong Yang, Misti Linaberry, Stephanie Noviello
BACKGROUND & AIMS: Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long-term efficacy and safety of daclatasvir-based regimens administered during clinical studies. METHODS: Patients enrolled within 6 months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow-up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non-responders or responders who relapsed, and characterization of liver disease progression...
September 21, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28935193/celastrol-inhibits-hepatitis-c-virus-replication-by-upregulating-heme-oxygenase-1-via-the-jnk-mapk-nrf2-pathway-in-human-hepatoma-cells
#7
Chin-Kai Tseng, Sung-Po Hsu, Chun-Kuang Lin, Yu-Hsuan Wu, Jin-Ching Lee, Kung-Chia Young
BACKGROUND AND PURPOSE: Celastrol, a quinone methide triterpene isolated from the root extracts of Tripterygium wilfordii, can greatly induce the gene expression activity of heme oxygenase-1 (HO-1) to achieve disease prevention and control. HO-1 induction was recently shown to result in anti-HCV activity by inducing type I interferon and inhibiting hepatitis C virus (HCV) NS3/4A protease activity. The aim of the present study is to evaluate the anti-HCV activity of celastrol and characterize its mechanism of inhibition...
September 19, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28932089/efficacy-and-safety-of-sofosbuvir-and-daclatasvir-in-treatment-of-kidney-transplantation-recipients-with-hepatitis-c-virus-infection
#8
Yan Xue, Li-Xin Zhang, Lei Wang, Tao Li, Yun-Dong Qu, Feng Liu
AIM: To assess the efficacy and safety of sofosbuvir and daclatasvir regimens for kidney transplantation (KT) patients with hepatitis C virus (HCV) infection. METHODS: This study enrolled a prospective cohort of consecutive Chinese KT patients with HCV infection. They were given sofosbuvir combined with daclatasvir, with or without ribavirin. They were monitored regularly during and after the treatment. RESULTS: Six patients were recruited in our prospective study cohort...
August 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28923507/pentagalloylglucose-a-highly-bioavailable-polyphenolic-compound-present-in-cortex-moutan-efficiently-blocks-hepatitis-c-virus-entry
#9
Patrick Behrendt, Paula Perin, Nicolas Menzel, Dominic Banda, Stephanie Pfaender, Marco P Alves, Volker Thiel, Phillip Meulemann, Che C Colpitts, Luis M Schang, Florian W R Vondran, Anggakusuma, Michael P Manns, Eike Steinmann, Thomas Pietschmann
Approximately 142 million people worldwide are infected with hepatitis C virus (HCV). Although potent direct acting antivirals are available, high costs limit access to treatment. Chronic hepatitis C virus infection remains a major cause of orthotopic liver transplantation. Moreover, re-infection of the graft occurs regularly. Antivirals derived from natural sources might be an alternative and cost-effective option to complement therapy regimens for global control of hepatitis C virus infection. We tested the antiviral properties of a mixture of different Chinese herbs/roots named Zhi Bai Di Huang Wan (ZBDHW) and its individual components on HCV...
September 18, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28906010/serial-changes-in-liver-stiffness-and-controlled-attenuation-parameter-following-direct-acting-antiviral-therapy-against-hepatitis-c-virus-genotype-1b
#10
Nobuhiko Ogasawara, Masahiro Kobayashi, Norio Akuta, Yoko Kominami, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Fumitaka Suzuki, Satoshi Saitoh, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada
Little information is available on the impact of direct-acting antiviral (DAA) therapy on changes in liver fibrosis and steatosis. Liver stiffness (LS) and controlled attenuation parameter (CAP) values were evaluated using transient elastography. The study subjects were 214 elderly patients infected with HCV genotype 1b who received 24-week daclatasvir and asunaprevir dual therapy. All patients of this retrospective study had no hepatocellular carcinoma before and during DAA therapy. LS and CAP were assessed before treatment (baseline), at end of treatment (EOT), and at 24, 48, 72 weeks (W) after EOT...
September 14, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28902678/brief-report-high-need-to-switch-cart-or-comedication-with-the-initiation-of-daas-in-elderly-hiv-hcv-coinfected-patients
#11
Elise J Smolders, Colette Smit, Clara T M M de Kanter, Anton S M Dofferiiof, Joop E Arends, Kees Brinkman, Bart Rijnders, Marc van der Valk, Peter Reiss, David M Burger
BACKGROUND: To describe the use of nonantiretroviral comedication and combination antiretroviral therapy (cART) in patients coinfected with HIV/hepatitis C virus (HCV) and to predict the potential for drug-drug interactions (DDIs) with direct-acting antivirals (DAAs) against HCV. METHODS: This is a retrospective, cross-sectional study, using the Dutch, nationwide ATHENA observational HIV cohort database. All patients with a known HIV/HCV coinfection on January 1, 2015, were included...
October 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28892235/beclabuvir-in-combination-with-asunaprevir-and-daclatasvir-for-hepatitis-c-virus-genotype-1-infection-a-systematic-review-and-meta-analysis
#12
Ali Mahmoud Ahmed, Mohamed Fahmy Doheim, Omar Mohamed Mattar, Nourin Ali Sherif, Duy Hieu Truong, Pham Thi Le Hoa, Kenji Hirayama, Nguyen Tien Huy
Daclatasvir, asunaprevir, and beclabuvir are direct-acting antivirals for patients with hepatitis C virus genotype 1 infection. This systematic review and meta-analysis investigating the efficacy and safety of this three-drug combination in HCV genotype 1 infection. Eleven electronic search engines were searched for relevant publications. Studies were screened for eligibility and data was extracted. The outcomes were pooled as event rate and risk ratio. The protocol was registered in PROSPERO (CRD42017054391)...
September 11, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28884930/retreatment-with-sofosbuvir-ledipasvir-with-or-without-lead-in-interferon-%C3%AE-injections-in-patients-infected-with-genotype-1b-hcv-after-unsuccessful-daclatasvir-asunaprevir-therapy
#13
Hayato Uemura, Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Shinpei Yamaba, Akira Fuchigami, Yoichi Saito, Keisuke Shiokawa, Yohei Fujii, Hiroshi Uchiya, Manabu Nakazawa, Satsuki Ando, Masamitsu Nakao, Daisuke Motoya, Kayoko Sugawara, Mie Inao, Yukinori Imai, Nobuaki Nakayama, Tomoaki Tomiya, Satoshi Mochida
AIMS: To improve the therapeutic efficacy of sofosbuvir/ledipasvir for the retreatment of patients after daclatasvir/asunaprevir, a customized therapy with or without lead-in interferon-β injections was performed according to the types of resistance-associated substitutions (RASs) in the NS5A region of genotype 1b HCV. METHODS: Thirty-three patients failing prior daclatasvir/asunaprevir received sofosbuvir/ledipasvir for 12 weeks. Patients with HCV carrying unfavorable NS5A-RASs and/or those with previous simeprevir administration were given lead-in interferon-β injections twice a day for 2 weeks; sequential changes in the NS5A-RASs during the injection period were evaluated using deep sequencing...
September 8, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28881052/asunaprevir-and-daclatasvir-for-recurrent-hepatitis-c-after-liver-transplantation-a-japanese-multicenter-experience
#14
Toru Ikegami, Yoshihide Ueda, Nobuhisa Akamatsu, Kohei Ishiyama, Ryoichi Goto, Akihiko Soyama, Kaori Kuramitsu, Masaki Honda, Masahiro Shinoda, Tomoharu Yoshizumi, Hideaki Okajima, Yuko Kitagawa, Yukihiro Inomata, Yonson Ku, Susumu Eguchi, Akinobu Taketomi, Hideki Ohdan, Norihiro Kokudo, Mitsuo Shimada, Katsuhiko Yanaga, Hiroyuki Furukawa, Shinji Uemoto, Yoshihiko Maehara
The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2%) patients...
September 7, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28880015/integrated-pharmacokinetic-viral-dynamic-model-for-daclatasvir-asunaprevir-in-treatment-of-patients-with-genotype-1-chronic-hepatitis-c
#15
He-Chuan Wang, Yu-Peng Ren, Yue Qiu, Jenny Zheng, Gai-Ling Li, Chuan-Pu Hu, Tian-Yan Zhou, Wei Lu, Liang Li
In order to develop an integrated pharmacokinetic/viral dynamic (PK/VD) model to predict long-term virological response rates to daclatasvir (DCV) and asunaprevir (ASV) combination therapy in patients infected with genotype 1 (GT1) chronic hepatitis C virus (HCV), a systematic publication search was conducted for DCV and ASV administered alone and/or in combination in healthy subjects or patients with GT1 HCV infection. On the basis of a constructed meta-database, an integrated PK/VD model was developed, which adequately described both DCV and ASV PK profiles and viral load time curves...
September 7, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/28874040/direct-acting-antiviral-agents-in-korean-patients-with-chronic-hepatitis-c-and-hemophilia-who-are-treatment-na%C3%A3-ve-or-treatment-experienced
#16
Hyun Woong Lee, Ki Young Yoo, Joung Won Won, Hyung Joon Kim
Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. Methods: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21; 1a, n=5) and four patients were genotype 2a/2b. Among 21 patients with genotype 1b, Y93H resistance-associated variants (RAVs) were detected in three patients (14.3%). We evaluated sustained virologic response (SVRs) at 12 weeks, as well as relapse and safety...
September 15, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28872737/chronic-hepatitis-caused-by-hepatitis-c-virus-showing-a-discrepancy-between-serogroup-and-genotype-because-of-intergenotypic-2b-1b-recombination-a-pitfall-in-antiviral-therapy-with-direct-acting-antivirals
#17
Hayato Kurata, Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Manabu Nakazawa, Satsuki Ando, Masamitsu Nakao, Daisuke Motoya, Kayoko Sugawara, Mie Inao, Yukinori Imai, Nobuaki Nakayama, Tomoaki Tomiya, Satoshi Mochida
A 40-year-old male patient with virologic relapse after daclatasvir plus asunaprevir therapy for a serogroup 1 hepatitis C virus (HCV) infection visited our hospital for retreatment. Virologic examinations revealed that a genotype 2b HCV strain carrying both NS3-S122N / D168A and NA5A-R30Q / L31M / Q54H / Y93H mutations had relapsed. The patient received sofosbuvir plus ribavirin therapy, but virologic relapse occurred once again. Sequencing of the HCV genome clarified an intergenotypic recombination of 2b and 1b with an estimated crossover point between nucleotides 3114 and 3115, corresponding to the N-terminal end of the NS3 region (DDBJ/EMBL/GenBank databases accession no...
September 5, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28856597/chemical-genetics-based-development-of-small-molecules-targeting-hepatitis-c-virus
#18
REVIEW
Guanghai Jin, Jisu Lee, Kyeong Lee
Hepatitis C virus (HCV) infection is a major worldwide problem that has emerged as one of the most significant diseases affecting humans. There are currently no vaccines or efficient therapies without side effects, despite today's advanced medical technology. Currently, the common therapy for most patients (i.e. genotype 1) is combination of HCV-specific direct-acting antivirals (DAAs). Up to 2011, the standard of care (SOC) was a combination of peg-IFNα with ribavirin (RBV). After approval of NS3/4A protease inhibitor, SOC was peg-IFNα and RBV with either the first-generation DAAs boceprevir or telaprevir...
August 30, 2017: Archives of Pharmacal Research
https://www.readbyqxmd.com/read/28846559/sofosbuvir-based-regimens-in-hiv-hcv-coinfected-patients-after-liver-transplantation-results-from-the-anrs-co23-cupilt-study
#19
Teresa Maria Antonini, Audrey Coilly, Emilie Rossignol, Claire Fougerou-Leurent, Jérôme Dumortier, Vincent Leroy, Aurélie Veislinger, Sylvie Radenne, Danielle Botta-Fridlund, François Durand, Pauline Houssel-Debry, Nassim Kamar, Valérie Canva, Philippe Perré, Victor De Ledinghen, Alexandra Rohel, Alpha Diallo, Anne-Marie Taburet, Didier Samuel, Georges-Philippe Pageaux, Jean-Charles Duclos-Vallée
BACKGROUND: A recurrence of hepatitis C virus after liver transplantation affects survival in HIV/HCV coinfected patients. This study assessed the efficacy and safety of sofosbuvir-based regimens in HIV/HCV coinfected patients following liver transplantation. METHODS: 29 HIV/HCV coinfected transplanted patients receiving tacrolimus, cyclosporine or everolimus-based immunosuppressive therapy were enrolled in the CUPILT cohort. Their antiviral treatment combined sofosbuvir, daclatasvir with or without ribavirin (n=10/n=6), or sofosbuvir, ledipasvir with or without ribavirin (n=2/n=11)...
August 24, 2017: Transplantation
https://www.readbyqxmd.com/read/28844749/immune-responses-in-daa-treated-chronic-hepatitis-c-patients-with-and-without-prior-rg-101-dosing
#20
Meike H van der Ree, Femke Stelma, Sophie B Willemse, Anthony Brown, Leo Swadling, Marc van der Valk, Marjan J Sinnige, Ad C van Nuenen, J Marleen L de Vree, Paul Klenerman, Eleanor Barnes, Neeltje A Kootstra, Hendrik W Reesink
BACKGROUND&AIMS: With the introduction of DAA's, the majority of treated chronic hepatitis C patients (CHC) achieve a viral cure. The exact mechanisms by which the virus is cleared after successful therapy, is still unknown. The aim was to assess the role of the immune system and miRNA levels in acquiring a sustained virological response after DAA treatment in CHC patients with and without prior RG-101 (anti-miR-122) dosing. METHODS: In this multicenter, investigator-initiated study, 29 patients with hepatitis C virus (HCV) genotype 1 (n = 11), 3 (n = 17), or 4 (n = 1) infection were treated with sofosbuvir and daclatasvir ± ribavirin...
August 24, 2017: Antiviral Research
keyword
keyword
40093
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"